Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-23T07:46:23.126Z Has data issue: false hasContentIssue false

Streptococcus pneumoniae–induced purpura fulminans in a woman with functional asplenia

Published online by Cambridge University Press:  04 March 2015

Jeremy M. Wojtowicz*
Affiliation:
Divisions of Emergency Medicine, McMaster University, Hamilton, ON
Graham Longden Jones
Affiliation:
Divisions of Respirology, McMaster University, Hamilton, ON
*
Department of Emergency Medicine, Hamilton General Hospital, 237 Barton Street East, HamiltonON L8L 2X2; [email protected]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Purpura fulminans is a rare complication of septic shock, often associated with Streptococcus pneumoniae. Patients with anatomic or functional asplenia are at increased risk for infection because of impairment of their ability to defend against encapsulated pathogens. We report the case of a previously healthy, unimmunized 33-year-old female with functional asplenia who presented in septic shock and purpura fulminans and died in spite of maximal resuscitative measures. The clinical presentation, diagnosis, and management of purpura fulminans are reviewed. Purpura fulminans is a rare condition that requires early diagnosis and aggressive management by emergency physicians.

Type
Case Report • Rapport de cas
Copyright
Copyright © Canadian Association of Emergency Physicians 2014

References

REFERENCES

1. Jakob, A, Alexandrakis, E, Rompel, R. Purpura fulminans secondary to respiratory infection. J Dtsch Dermatol Ges 2009;7:135–8.Google Scholar
2. Francis, RB Jr. Acquired purpura fulminans. Semin Thromb Hemost 1990;16:310–25, doi:10.1055/s-2007-1002684.Google Scholar
3. Holdsworth, R, Irving, A, Cushieri, A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg 1991;78:1031–8, doi:10.1002/bjs.1800780904.Google Scholar
4. Bisharat, N, Omari, H, Lavi, I, et al. Risk of infection and death among post-splenectomy patients. J Infect 2001;43:182–6, doi:10.1053/jinf.2001.0904.Google Scholar
5. Melles, DC, de Marie, S. Prevention of infections in hyposplenic and asplenic patients: an update. Neth J Med 2004;62:4552.Google Scholar
6. Davidson, RN, Wall, RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 2001;7:657–60, doi:10.1046/j.1198-743x.2001.00355.x.Google Scholar
7. Jenks, PJ, Jones, E. Infections in asplenic patients. Clin Microbiol Infect 1996;1:266–72.Google Scholar
8. Chalmers, E, Cooper, P, Forman, K, et al. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child 2011;96:1066–71, doi:10.1136/adc.2010.199919.Google Scholar
9. Warner, PM, Kagan, RJ, Yakuboff, KP, et al. Current management of purpura fulminans: a multicenter study. J Burn Care Rehabil 2003;24:119–26, doi:10.1097/01.BCR.0000066789.79129.C2.Google Scholar
10. Basem, M, Corazza, G. Hyposplenism: a comprehensive review. Part 1: basic concepts and causes. Hematology 2007;12:113, doi:10.1080/10245330600938422.Google Scholar
11. Price, VE, Blanchette, VS, Ford-Jones, EL. The prevention and management of infections in children with asplenia or hyposplenism. Infect Dis Clin North Am 2007;21:697710, doi:10.1016/j.idc.2007.07.002.Google Scholar
12. Basem, M, Thawani, N, Sae-Tia, S, et al. Hyposplenism: a comprehensive review. Part 2: clinical manifestations, diagnosis and management. Hematology 2007;12:8998, doi:10.1080/10245330600938463.Google Scholar
13. Piette, WW. The differential diagnosis of purpura from a morphologic perspective. Adv Dermatol 1994;9:323.Google Scholar
14. Rivers, E, Nguyen, B, Havstad, S, et al. Early goal directed therapy in the early treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368–77, doi:10.1056/NEJMoa010307.Google Scholar
15. Nguyen, HB, Rivers, EP, Abrahamian, FM, et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med 2006;48:2854.Google Scholar
16. Smith, OP, White, B, Vaughan, D, et al. Use of protein C concentrate, heparin and haemodiafiltration in meningococcus induced purpura fulminans. Lancet 1997;350:1590–3, doi:10.1016/S0140-6736(97)06356-3.Google Scholar
17. Veldman, A, Fischer, D, Wong, FY, et al. Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients. Crit Care 2010;14:R156, doi:10.1186/cc9226.Google Scholar
18. Public Health Agency of Canada. Canadian immunization guide 2006. 7th ed. Available at: (accessed July 25, 2011).Google Scholar